Recent Advances in Curcumin Drug Delivery Systems Based on Nano Compounds and Their Therapeutic Application

ABSTRACT Curcumin is a polyphenol that has been found to have therapeutic potential encompassing antioxidant, anti‐inflammatory, anticancer, and neuroprotective properties. However, its clinical translation has been significantly hindered by poor aqueous solubility, chemical instability, and limited bioavailability. Nonotechnology has emerged as a transformative approach to overcome these limitations. This review systematically explores the advancements in nanostructured curcumin delivery systems from 2020 to 2025, emphasizing polymeric nanoparticles, dendrimers, lipid‐based nanocarriers (liposomes, NLCs, SLNs), cyclodextrins, hydrogels, inorganic nanocarriers (e.g., MSNs, AuNPs), and hybrid platforms. These nanoformulations enhance curcumin's physicochemical stability, enable targeted and sustained drug release, and improve cellular uptake. Furthermore, co‐delivery strategies with agents like piperine and chemotherapeutics show synergistic therapeutic benefits. A complete in vitro and in vivo evaluation confirms curcumin's efficacy in managing cancer, metabolic syndromes, inflammatory disorders, and neurodegeneration. Despite these advances, translational barriers including regulatory ambiguity, scalability challenges, and formulation reproducibility persist. This review advocates for multidisciplinary collaborations to standardize nanocurcumin development pipelines and align industrial production with clinical protocols. Nanoformulated curcumin represents a strategic innovation for the pharmaceutical industry; its successful translation will depend on regulatory harmonization and holds a strong promise as a next‐generation therapeutic agent across multiple disease spectra.